Grace Therapeutics, Inc. GRCE

2.12 (0.04) (1.85%) as of 25 Sep
Market cap
$45.4M
P/E
0.0×
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Quick Ratio
11.02 7.92 14.56 13.56
Current Ratio
11.47 8.10 14.96 13.89
Net Debt/EBITDA
0.86 5.65 7.63 6.67
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.20 1.44 0.96 3.35
Capex/Depreciation
0.00 0.00 0.00 0.00
Interest Coverage
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.71 0.74 0.72 0.74
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Yield
— — — —
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(0.19) (0.10) (0.13) (0.20)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.19) (0.10) (0.13) (0.20)
Cash per Share
0.80 1.03 1.10 1.06
Shareholders Equity per Share
2.79 3.87 3.83 3.94
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
2.79 3.87 3.83 3.94
Free Cash Flow
(3.22) (1.69) (2.23) (3.14)
Working Capital
13.08 15.23 17.93 16.05
Net Current Asset Value
12.47 14.62 15.62 13.54
EV/EBIT
— — — —
Net Profit Margin
0.00% 0.00% 0.00% 0.00%
Other line items
Average Receivables
0.02 0.07 0.16 0.22
Average Payables
1.78 2.04 1.63 1.96
Average Assets
59.94 69.32 64.86 65.96
Average Common Equity
55.88 65.25 58.52 59.48

Fold the line items

Columns are period end dates